[go: up one dir, main page]

PT3622953T - Tratamento combinado do cancro - Google Patents

Tratamento combinado do cancro

Info

Publication number
PT3622953T
PT3622953T PT192051043T PT19205104T PT3622953T PT 3622953 T PT3622953 T PT 3622953T PT 192051043 T PT192051043 T PT 192051043T PT 19205104 T PT19205104 T PT 19205104T PT 3622953 T PT3622953 T PT 3622953T
Authority
PT
Portugal
Prior art keywords
cancer
combined treatment
treatment
combined
Prior art date
Application number
PT192051043T
Other languages
English (en)
Original Assignee
Scandion Oncology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology As filed Critical Scandion Oncology As
Publication of PT3622953T publication Critical patent/PT3622953T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT192051043T 2016-05-17 2017-05-17 Tratamento combinado do cancro PT3622953T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17

Publications (1)

Publication Number Publication Date
PT3622953T true PT3622953T (pt) 2021-04-21

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
PT177265733T PT3458052T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro
PT192051043T PT3622953T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT177265733T PT3458052T (pt) 2016-05-17 2017-05-17 Tratamento combinado do cancro

Country Status (19)

Country Link
US (2) US11103481B2 (pt)
EP (3) EP3458052B1 (pt)
JP (1) JP7033554B2 (pt)
CN (4) CN119548494A (pt)
AU (1) AU2017266724B2 (pt)
BR (1) BR112018073518A2 (pt)
CA (1) CA3023202A1 (pt)
CY (2) CY1122541T1 (pt)
DK (2) DK3622953T3 (pt)
ES (2) ES2770374T3 (pt)
HR (2) HRP20200076T1 (pt)
HU (2) HUE053744T2 (pt)
LT (2) LT3622953T (pt)
PL (2) PL3622953T3 (pt)
PT (2) PT3458052T (pt)
RS (2) RS61786B1 (pt)
SI (2) SI3458052T1 (pt)
SM (2) SMT202100245T1 (pt)
WO (1) WO2017198700A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103481B2 (en) * 2016-05-17 2021-08-31 Scandion Oncology A/S Combination treatment of cancer
US11530181B2 (en) 2018-02-22 2022-12-20 University Of Florida Research Foundation, Incorporated IL-6 inhibitors and methods of treatment
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en) 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
EP4355324A1 (en) 2021-06-14 2024-04-24 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
EP4355322A1 (en) 2021-06-14 2024-04-24 Scandion Oncology A/S Methods of increasing the plasma drug exposure of anticancer agents
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts
WO2025125679A1 (en) 2023-12-15 2025-06-19 Scandion Oncology A/S Improved anti-cancer treatment regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
IL132107A (en) 1997-04-22 2004-09-27 Neurosearch As Substituted phenyl derivatives, their preparation and use
HUP0103673A3 (en) 1998-10-22 2003-03-28 Neurosearch As Substituted phenyl derivatives, their preparation and use
MXPA05001235A (es) 2002-08-01 2005-06-08 Neurosearch As Compuestos utiles para el tratamiento de enfermedades sensibles a la terapia antiangiogenetica.
AU2004247429B2 (en) * 2003-06-17 2010-01-28 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers
WO2005075479A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Dimeric azacyclic compounds and their use
CA2591616A1 (en) 2004-12-17 2006-06-22 Neurosearch A/S Diphenylurea derivatives useful as potassium channel activators
US7985761B2 (en) 2006-03-14 2011-07-26 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers or BKCa channel modulators
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft LRRC8 proteins and protein complexes and methods for identification of channel modulators
EP3064207B1 (en) 2015-03-04 2017-12-20 Scandion Oncology A/S 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
US11103481B2 (en) * 2016-05-17 2021-08-31 Scandion Oncology A/S Combination treatment of cancer

Also Published As

Publication number Publication date
LT3622953T (lt) 2021-04-26
LT3458052T (lt) 2020-02-10
CY1122541T1 (el) 2021-01-27
CN119548493A (zh) 2025-03-04
CA3023202A1 (en) 2017-11-23
CN119564679A (zh) 2025-03-07
SI3622953T1 (sl) 2021-05-31
JP2019519506A (ja) 2019-07-11
ES2870805T3 (es) 2021-10-27
SMT202100245T1 (it) 2021-05-07
EP3854393A1 (en) 2021-07-28
CN119548494A (zh) 2025-03-04
US20210353596A1 (en) 2021-11-18
AU2017266724B2 (en) 2022-04-14
RS61786B1 (sr) 2021-06-30
HUE053744T2 (hu) 2021-07-28
PL3622953T3 (pl) 2021-08-16
SI3458052T1 (sl) 2020-04-30
DK3622953T3 (da) 2021-04-26
SMT202000053T1 (it) 2020-03-13
WO2017198700A1 (en) 2017-11-23
EP3622953A1 (en) 2020-03-18
BR112018073518A2 (pt) 2019-03-19
RS59844B1 (sr) 2020-02-28
DK3458052T3 (da) 2020-02-03
EP3622953B1 (en) 2021-03-17
ES2770374T3 (es) 2020-07-01
US20190269654A1 (en) 2019-09-05
PT3458052T (pt) 2020-02-03
US11103481B2 (en) 2021-08-31
EP3458052A1 (en) 2019-03-27
CY1124242T1 (el) 2022-07-22
PL3458052T3 (pl) 2020-06-29
EP3458052B1 (en) 2019-11-06
AU2017266724A1 (en) 2018-12-20
JP7033554B2 (ja) 2022-03-10
HUE047542T2 (hu) 2020-04-28
HRP20210572T1 (hr) 2021-05-14
CN109475535A (zh) 2019-03-15
US11903927B2 (en) 2024-02-20
HRP20200076T1 (hr) 2020-04-03

Similar Documents

Publication Publication Date Title
PL3283527T3 (pl) Leczenie skojarzone nowotworów
IL255261A0 (en) Methods for treating cancer
IL249065A0 (en) Combination therapies for the treatment of cancer
EP3488001A4 (en) TREATMENT OF CANCER
PL3288581T3 (pl) Sposób leczenia nowotworu
IL263802A (en) Cancer treatment combinations
HUE059694T2 (hu) Készítmény rák kezelésére
PT3458052T (pt) Tratamento combinado do cancro
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
IL258521B1 (en) Combination therapy for the treatment of cancer
PL3197456T3 (pl) Leczenie nowotworów
IL252096A0 (en) Microneedle arrays for cancer therapy applications
IL265697B1 (en) Treatment of prostate cancer
LT3576740T (lt) Vėžio gydymas
PL3525774T3 (pl) Leczenie lazofoksyfenem raka piersi er+
EP3413927A4 (en) CANCER THERAPY
PT3134119T (pt) Tratamento do cancro
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
IL246558A0 (en) Novel methods for treating cancer
IL263835A (en) Exosome-guided treatment of cancer
IL264277A (en) Crebbp related cancer therapy
EP3484477A4 (en) CANCER TREATMENT
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T5 (da) Cancerbehandling